IN BRIEF: Immupharma Says L1 Capital Converts USD200,000 Of Security

Immupharma PLC - London-based pharmaceutical company - Says US healthcare investor L1 Capital ...

Alliance News 23 November, 2020 | 2:29PM
Email Form Facebook Twitter LinkedIn RSS

Immupharma PLC - London-based pharmaceutical company - Says US healthcare investor L1 Capital Global Opportunities Master Fund converts USD200,000 plus interest of convertible security issued pursuant to convertible security deed entered into in June. Says conversion price is 11 pence per share resulting in the issue of 1.4 million shares to L1 Capital.

In June, Immupharma said it would issue USD3 million of securities to L1 Capital and Lind Global Macro Fund LP, with a maturity period of 18 months, adding that at any time during the maturity period, the investors may convert their securities - in whole or in part - to 13.1 million shares in the company at a price of 17.96p.

At the time, Immupharma said net proceeds from the investment will be used to fund continued expansion of its research & development programmes and for general working capital.

Current stock price: 13.44p

Year-to-date change: down 16%

By Ife Taiwo; ifetaiwo@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
ImmuPharma PLC 2.14 GBX -0.09 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures